Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of Ankylosing Spondylitis~* Has active disease despite concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) treatment or is intolerant to NSAIDs~Exclusion Criteria:~* Pregnant or lactating females~* Currently receiving or previous use of a Tumor Necrosis Factor (TNF) inhibitor or any biological agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib 2 mg (Type: EXPERIMENTAL): None
- Tofacitinib 5 mg (Type: EXPERIMENTAL): None
- Tofacitinib 10 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).